No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US Stock MarketDetailed Quotes
PHAT Phathom Pharmaceuticals
- 7.450
- -0.370-4.73%
Close Dec 20 16:00 ET
- 7.450
- 0.0000.00%
Post 20:01 ET
509.41MMarket Cap-1.30P/E (TTM)
7.830High7.390Low2.48MVolume7.710Open7.820Pre Close18.63MTurnover4.44%Turnover RatioLossP/E (Static)68.38MShares19.71052wk High-2.72P/B415.18MFloat Cap6.06552wk Low--Dividend TTM55.73MShs Float64.540Historical High--Div YieldTTM5.63%Amplitude5.840Historical Low7.523Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Shareholders in Phathom Pharmaceuticals (NASDAQ:PHAT) Have Lost 66%, as Stock Drops 12% This Past Week
Do You Believe in the Growth Potential of Phathom Pharmaceuticals (PHAT)?
Phathom Pharmaceuticals Analyst Ratings
Needham Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Maintains Target Price $28
Phathom Pharmaceuticals: Undervalued Opportunity With Strategic Moves for Extended Exclusivity
Express News | Phathom Pharmaceuticals Inc: Exclusivity Period Is Until May 3, 2032
Heat List
US
Overall
Symbol
Price
% Chg
No Data